Erectile dysfunction Board decisions

The Board remands the claims for service connection for diabetes mellitus type II, a brain tumor, erectile dysfunction, and diabetic sensory peripheral neuropathy to further develop evidence of herbicide exposure.

The Board granted service connection for GERD, based on secondary aggravation by the Veteran's service-connected hypertension. The other claims were remanded for further development.

The Board denied service connection for bilateral tinnitus, ED, OSA, visual impairment, left-hand disability, and acquired psychiatric disability. However, it granted service connection for a back condition (lumbosacral strain) and remanded claims for other disabilities including right hand, left elbow, right elbow, and right knee.

The Board denied service connection for lumbar spine, cervical spine, bilateral hearing loss, and left shoulder disabilities. The claims for erectile dysfunction and a respiratory disability were remanded.

The Board denied service connection for multiple conditions, including hyperlipidemia, low testosterone, epididymitis, ED, prostatectomy, a mass of the parotid gland, prostate cancer, stress urinary incontinence, and other related conditions.

The Board granted service connection for diabetes mellitus type II with erectile dysfunction, right and left lower extremity diabetic neuropathies (sciatic and femoral nerves), and hypertension, all as due to herbicide exposure on a facts-found basis.

The Board granted service connection for erectile dysfunction, finding that it is at least as likely as not related to the Veteran's service-connected major depressive disorder with anxious distress.

The Board granted service connection for a psychiatric disability, diagnosed as major depressive disorder, and assigned an initial rating of 10 percent for bilateral hearing loss. Other claims were denied.

The Board granted a rating of 20 percent for right lower extremity sciatic radiculopathy, but remanded claims for service connection for an acquired psychiatric disability, ED, GERD, and IBS.

The Board denied the veteran's claims for earlier effective dates and service connection, as well as an increased rating for bilateral hearing loss.

The Board dismissed the motions for revision of clear and unmistakable error in various rating decisions, including those related to service connection and ratings for multiple conditions. The claims for service connection were remanded.

The Board remands the claims for service connection for tinnitus and erectile dysfunction (ED) to correct pre-decisional duty to assist errors.

The Board granted service connection for various conditions, including neck disability manifested by pain and diabetes mellitus type II, secondary to the Veteran's service-connected bilateral knee degenerative arthritis. The other conditions were also granted as they are caused by the now-service-connected diabetes mellitus type II.

The Board remands the claims for service connection for unspecified depressive disorder and erectile dysfunction, to include as secondary to unspecified depressive disorder, due to pre-decisional duty to assist errors.

The Veteran's adjustment disorder with depressed mood was granted a 70 percent rating, but erectile dysfunction was denied a compensable rating.

The Board granted an initial disability rating of 10 percent for irritable bowel syndrome (IBS) but remanded the claim for service connection for erectile dysfunction (ED).

The Board granted an increased rating of 70 percent for the acquired psychiatric condition effective March 4, 2024.

The Board remands the claims for service connection for tinnitus, erectile dysfunction, an acquired psychiatric disorder, and chronic sinusitis to provide the Veteran with VA examinations.

The Board granted service connection for tonsilitis and a left shoulder disability, but denied service connection for residuals of traumatic brain injury (TBI), right ankle, and left ankle disabilities. The claim for a higher rating for GERD was also denied.

The Board granted an effective date of March 2, 2023 for heart disease and September 28, 2023 for chronic renal failure, while denying earlier effective dates for PTSD, migraines, diabetes mellitus type II, hypertension, and bilateral hearing loss. The Board also granted a 70 percent evaluation for PTSD.